This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Health Winners & Losers

Health indices closed out the week fairly flat as some stocks benefitted from analyst actions, while others fell because of trial results and lawsuits.

Cadence Pharmaceuticals (CADX) said Friday that in a pivotal late-stage trial its IV-administered Acetavance for pain and fever didn't meet a primary endpoint.

Shares plunged $8.43, or 60.3%, to $5.59 after the company said that in a late stage study its Acetavance for post-operative pain and fever didn't demonstrate a statistically significant reduction in patients' pain over 48 hours compared to placebo after abdominal gynecologic surgery. Acetavance did reduce fever in a separate, smaller study, and was safe and well-tolerated in both studies, according to the company.

The stock tugged at the Nasdaq biotechnology index, which was down 2.99, or 0.35%, at 854.56.

Also falling, CryoLife (CRY - Get Report)said it faces a $110 million lawsuit from a patient who had an infection following a Meniscal allograft, a transplant used for patients who have significantly damaged knees. The Kennesaw, Ga.-based company, which has been sued successfully on similar allegations in the past, called the allegations inaccurate. Shares were down $1.43, or 15.3%, to $7.90.

In the other direction: Usana Health Sciences (USNA - Get Report) said Friday that the SEC has ended a probe and won't seek legal action. The SEC began investigating allegations of fraud and concerns about the company's marketing model in March. Shares rose $8.75, or 24.6%, to $44.32.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
CADX $0.00 0.00%
IDIX $24.50 0.20%
CRY $10.09 0.00%
ILMN $191.23 0.00%
USNA $120.23 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs